Skip to content
Cardiff Oncology
  • About
    • Leadership
    • Press releases
    • Media
  • Onvansertib
  • Pipeline
  • Clinical Programs
    • mCRC
    • mPDAC
    • Scientific Publications
  • For Investors
  • Contact Us

Author: nathan

Expanded Access Program (EAP) of PLK1 Inhibitor Onvansertib in Combination with FOLFIRI and Bevacizumab for Treatment of Patients with KRAS-mutant Metastatic Colorectal Cancer

Posted on May 14, 2021January 10, 2022 by nathan
Expanded Access Program (EAP) of PLK1 Inhibitor Onvansertib in Combination with FOLFIRI and Bevacizumab for Treatment of Patients with KRAS-mutant Metastatic Colorectal Cancer
Cardiff logo

11055 Flintkote Ave.
San Diego, CA 92121

858-952-7570

  • LinkedIn
  • Twitter
  • Facebook
  • Contact Us
  • Terms Of Use
  • Privacy Policy

© Cardiff Oncology, Inc. All rights reserved. Site Design